Across the span of a diagnosis, the years a person has left can be counted, and for African-American patients with head and neck squamous cell carcinoma that count has been strikingly shorter than for European American patients. A review led by researchers at the University of Maryland suggests that some of this inequality may already be inscribed in the tumors themselves, shaped by the ancestry carried in each person's DNA rather than by the race they report. The findings do not dismiss the long-known roles of tobacco, alcohol, HPV, and access to care, but they widen the frame to ask whether
Genetic Ancestry Emerges as Key Factor in Head and Neck Tumor Biology and Survival Disparities
African-American patients with head and neck squamous cell carcinoma survive on average about half as long as European American patients after diagnosis.
Ancestry, rather than self-identified race, proved a stronger predictor
Mark
Start with the headline number. Two and a half years versus 4.8. Is the study saying genetics causes that gap?
Mimi
Not that cleanly. It says ancestry-linked tumor biology may help explain it. Smoking, drinking, HPV, delayed diagnosis and access to care all remain essential factors in the authors' framing.
Luke
Right, and the gap itself is an average from the data, not something the review proves is genetic. The reporting doesn't say how much of the difference biology accounts for. That's unknown.
Mark
What did they actually look at?
Mimi
523 patients in The Cancer Genome Atlas. They compared tumor mutations, DNA copy gains and losses, and gene activity against genetic ancestry.
Luke
Worth noting this is a review study drawing on an existing database. It's not a new trial, and nothing here shows a treatment changing outcomes.
Mark
The detail about ancestry beating self-identified race seems important.
Mimi
It is. Self-identified race is a social category. Ancestry is measured in DNA, and it predicted tumor differences more strongly.
Luke
Fair, but the source gives no effect sizes or breakdown by group, so I can't tell how strong strong is.
Mark
And the practical point?
Mimi
Gaykalova says precision medicine needs to account for ancestry-linked biology alongside social factors, so treatments could eventually be better targeted.
Luke
Eventually is the key word. Some alterations may be protective and others aggressive, but which ones and what to do about them hasn't been spelled out.
Il Polso
- African-American patients with head and neck squamous cell carcinoma survive about 2.5 years on average, while European American patients survive about 4.8 years.
- A review of 523 patient tumors suggests ancestry, not self-identified race, best tracks the genetic differences that separate one cancer from another.
- Those differences reach into tumor mutations, DNA copy changes, and gene activity, touching how fast cells divide, how they respond to chemotherapy, and whether they spread.
- The gap is not explained by smoking, drinking, or HPV alone, pushing researchers to test ancestry-linked biology alongside social factors.
- The work is a review of existing data, so the next step is identifying which ancestry-linked alterations drive worse outcomes and whether treatment can be adjusted to match them.
Across the span of a diagnosis, the years a person has left can be counted, and for African-American patients with head and neck squamous cell carcinoma that count has been strikingly shorter than for European American patients. A review led by researchers at the University of Maryland suggests that some of this inequality may already be inscribed in the tumors themselves, shaped by the ancestry carried in each person's DNA rather than by the race they report. The findings do not dismiss the long-known roles of tobacco, alcohol, HPV, and access to care, but they widen the frame to ask whether biology, inherited through ancestry, has been quietly part of the story all along.
African-American patients diagnosed with head and neck squamous cell carcinoma survive, on average, about two and a half years after diagnosis. European American patients with the same cancer survive about 4.8 years. A new review from the University of Maryland asks whether part of that difference is already present in the tumors.
The team, from the School of Medicine's Institute for Genome Sciences and the Greenebaum Comprehensive Cancer Center, published in Cancer and Metastasis Reviews. They examined 523 patients in The Cancer Genome Atlas and found that genetic ancestry shapes patterns of tumor mutations, DNA copy changes, and gene activity. These patterns relate to how quickly cells multiply, how they respond to chemotherapy, and whether they spread. Some alterations may protect, others may drive aggression.
A key finding is that ancestry predicted tumor genetic differences more strongly than self-identified race. That matters because most disparity research relies on the race people report, not the DNA in their cells. The authors are clear that smoking, drinking, HPV, and delayed diagnosis remain essential. Their point is that ancestry-linked biology may be an additional thread in the same story.
First author Madeleine Ndahayo and senior author Daria Gaykalova stress that social factors still matter, but biological drivers must be considered if precision medicine is to work for everyone. The review calls for ancestry-linked tumor biology to be studied alongside lifestyle and socioeconomic status, not instead of them.
Because this is a review of existing data rather than a clinical trial, it raises questions more than answers them. The next task is to identify which ancestry-associated alterations drive poorer outcomes, and whether treatments can be tailored to them.
African-American patients diagnosed with head and neck squamous cell carcinoma survive, on average, two and a half years. European American patients with the same cancer survive an average of 4.8 years, nearly twice as long. A new review from the University of Maryland suggests that part of that gap may be written into the tumors themselves.
The work was led by researchers at the University of Maryland School of Medicine's Institute for Genome Sciences and the University of Maryland Greenebaum Comprehensive Cancer Center. It appears in the journal Cancer and Metastasis Reviews. The team analyzed data from 523 patients held in The Cancer Genome Atlas, described as the largest biological database for several cancer types. Their question was whether genetic differences in the tumors line up with patients' ancestry, and whether those differences affect how the cancers behave.
They found that they do. According to the study, genetic ancestry influences patterns of tumor mutations, gains or losses of DNA copies, and gene activity. These changes are tied to how quickly tumor cells divide, whether they respond to chemotherapy, and whether they spread to other organs. The authors say some of the alterations may be protective, while others may contribute to more aggressive disease.
One finding stands out. Ancestry, rather than self-identified race, proved a stronger predictor of genetic differences between tumors. That distinction matters because most disparity research relies on the race people report for themselves, not on the DNA in their cells.
The established explanations are not set aside. Head and neck cancer has long been linked to tobacco and alcohol use and to infection with the human papillomavirus. Earlier research has suggested that survival differences between patients who identify as Black and those who identify as white may relate to differences in smoking or drinking rates, or to delayed diagnosis stemming from limited access to care. The new review treats these as essential factors. Its argument is that tumors arising in people of different genetic ancestries can also carry distinct biological features, including changes in key genes governing growth and treatment response.
The first author is Madeleine Ndahayo, a student researcher at the medical school. The senior author is Daria Gaykalova, Ph.D., a scientist at the Institute for Genome Sciences and an associate professor of otorhinolaryngology and head and neck surgery. Gaykalova said genetic ancestry reflects biologically encoded variation in DNA. In her words, the review reinforces that social factors matter, but biological drivers linked to ancestry must also be considered if precision medicine is to be truly effective.
The authors say these biological differences could help explain variation in treatment response and survival, and could support more precise and effective treatments for people with this cancer. The review calls for ancestry-linked tumor biology to be examined alongside social determinants such as lifestyle habits and socioeconomic status, not in place of them.
The piece is a review of existing data, not a new clinical trial, so it points toward questions rather than settling them. The next step is to find out which specific ancestry-associated alterations drive worse outcomes, and whether treatment can be adapted to them.
Citazioni salienti
Genetic ancestry reflects biologically encoded variation in DNA; social factors matter, but ancestry-linked biological drivers must also be considered for effective precision medicine.— Dr. Daria Gaykalova, senior author
Vuoi la storia completa?
Leggi l'originale su Medical Xpress ↗
Science & Space